Designing cardiac assays for multi-year discovery and safety pipelines

Thursday, March 12 at 15:00 GMT | 16:00 CET | 10:00 EST | 07:00 PST

Cardiac assays should not be short-term. Yet most discovery and safety teams still build multi-year programs on short-lived cardiomyocyte batches. That creates variability, repeated revalidations, and rising costs per program, driven by delays and increased decision risk as discovery and safety pipelines advance. 

This webinar aims to introduce a different model.

Ncyte vCardiomyocytes are manufactured as a single multi-billion-cell batch that supports three to five years of consistent assay performance. Data remain stable across MEA, impedance, and calcium imaging, while requiring around forty percent fewer cells per well. The result? Predictable data, fewer reruns, and a materially lower operational and economic burden across long discovery and safety.

We will walk you through the scientific rationale, show real performance data, and quantify the economic impact using a live cost model supported with internal benchmarks

Key learning objectives

• Viability, identity, and transcriptomic retention data
• Longitudinal MEA stability data from a single 10B-cell batch
• Cross-modality consistency across impedance and calcium imaging
• Cost modeling showing validation event reduction and cumulative impact
• When stable supply becomes a strategic advantage rather than a procurement issue 

Who should attend?

This session is designed for: 

• Scientists running MEA, impedance, or calcium workflows
• Teams managing long-term cardiac safety programs
• Technical leads responsible for assay continuity and revalidation
• Program leaders evaluating operational risk in preclinical pipelines
  

Register to review the data!

Speakers

Mariana holds a PhD in molecular biology from the University of SanMartin (Buenos Aires) and has worked at several universities in the US for more than eight years, specializing in stem cell biology. Throughout her experience in academic research, she gained distinct knowledge and expertise in both disease modeling and biobank building, and in the differentiation of iPSCs into cardiac and neuronal cell types. In 2022, Mariana joined the manufacturing team at Ncardia, where she pursues new iPSC manufacturing procedures and scale-up processes to support their application in regenerative medicine and drug discovery.